Literature DB >> 11272687

Acute and chronic urticaria. Challenges and considerations for primary care physicians.

G Krishnaswamy1, G Youngberg.   

Abstract

Urticaria and angioedema are common dermatologic problems seen by primary care physicians. A carefully taken history, physical examination, specific tests, and skin biopsy often provide useful diagnostic information. In patients with chronic urticaria, urticarial vasculitis and diseases that mimic urticaria need to be ruled out. A variety of treatment options are available for patients with urticaria and urticarial vasculitis. Pharmacologic therapy is useful when the specific cause is undetermined. When a trigger has been identified, the patient must avoid exposure to it. Patient education is an important component of management and should include instructions on crisis management, particularly for patients who have angioedema or a tendency for anaphylaxis.

Entities:  

Mesh:

Year:  2001        PMID: 11272687     DOI: 10.3810/pgm.2001.02.861

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  4 in total

1.  Risperidone-induced recurrent giant urticaria.

Authors:  Biswaranjan Mishra; Sahoo Saddichha; Rakesh Kumar; Sayeed Akhtar
Journal:  Br J Clin Pharmacol       Date:  2007-10       Impact factor: 4.335

2.  High-dose anti-histamine use and risk factors in children with urticaria.

Authors:  Pınar Uysal; Sibelnur Avcil; Duygu Erge
Journal:  Turk Pediatri Ars       Date:  2016-12-01

3.  Risperidone-induced Erythema Multiforme Minor.

Authors:  Shreyas Shrikant Pendharkar; Shilpa Avinash Telgote; Amol Jadhav; Sachin Bhojne
Journal:  Indian J Psychol Med       Date:  2017 Nov-Dec

4.  Efficacy and safety of Xiaofeng powder (xiao feng san) in treating urticaria: A protocol for a systematic review and meta-analysis of randomized controlled trials.

Authors:  Guoming Chen; Jinlong Zhao; Tengyu Chen; Zhaoping Zhang; Chuyao Huang; Zhirui Xu; Hua Xu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.